Our evaluation of AYA22T-R2-13’s cell cytolytic activity in hypermutated (HCT-15) and non-hypermutated tumor cell lines (COLO205) [60] demonstrated its significant enhancement of CD8+ T cell and NK cell cytolytic activity in vitro. The gene discussed is CD8A; the disease is neoplasm.